Back to top
more

Adamas Pharmaceuticals, Inc. (ADMS)

(Delayed Data from NSDQ)

$6.39 USD

6.39
241,532

+0.11 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.38 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.

Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?

by Zacks Equity Research

Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.

What's in Store for Select Medical (SEM) Earnings in Q1?

by Zacks Equity Research

Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.

Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?

by Zacks Equity Research

Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

by Zacks Equity Research

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

Nutanix (NTNX) to Post Q3 Earnings: What Lies in Store?

by Zacks Equity Research

Nutanix's (NTNX) third-quarter fiscal 2020 results are likely to have benefited from demand for its hybrid cloud solutions.

Intuit (INTU) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Intuit's (INTU) fiscal Q3 earnings are likely to have gained from buoyant demand for Quickbooks Online. However, an extension on tax filing deadline is likely to have weighed on the top line.

Palo Alto (PANW) to Report Q3 Earnings: What Lies in Store?

by Zacks Equity Research

Palo Alto's (PANW) third-quarter fiscal 2020 earnings are likely to have gained from the strong adoption of Prisma and Cortex platforms.

NortonLifeLock (NLOK) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

NortonLifeLock's (NLOK) Q4 results are likely to reflect growth in bookings. However, high tax payments are likely to have put cash flow under pressure.

Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss

by Zacks Equity Research

Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.

EchoStar (SATS) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Impact of higher churn rate with decline in enterprise services are likely to get reflected on EchoStar's (SATS) first-quarter 2020 results.

A10 Networks (ATEN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

A10 Networks' (ATEN) first-quarter 2020 performance is likely to have benefited from business optimization and a strong product line.

Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy

by Zacks Equity Research

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Generic Drugs Industry's Prospects Uncertain Amid Coronavirus

by Zacks Equity Research

Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.

Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adamas (ADMS) delivered earnings and revenue surprises of 6.74% and 0.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?